MetaCap

Cronos Group Financial Ratios

NASDAQ: CRONHealth Care Medicinal Chemicals and Botanical Products USD

3.23+0.01 (+0.31%)

At close: Oct 9, 4:00 PM ET · Delayed 15 min

Cronos Group ratio analysis

Cronos Group earned a net margin of -6.4% in FY 2025, down from 34.9% a year earlier. Gross margin was 42.8% compared with a median of 15.7% over the prior 8 years. Return on equity reached -0.9%, meaning Cronos Group generated -0.01 dollars of profit for every dollar of shareholders' equity.

Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.

Summary generated from market data by MetaCap's automated system. Methodology

Cronos Group financial ratios (annual)

Cronos Group annual financial ratios
RatioFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
P/E ratio (at fiscal year end)—18.82————2.14——
Price / sales7.066.729.1311.0422.4952.2393.09167.42—
Price / book0.950.740.720.841.091.431.2613.67—
Gross margin42.8%21.4%13.7%17.8%-27.3%-55.3%-74.1%51.3%50.0%
Operating margin-11.9%-65.1%-97.2%-128.4%-452.2%-469.6%-645.5%-168.7%-194.5%
Net margin-6.4%34.9%-84.8%-194.5%-613.5%-156.5%4,911.6%-178.5%-47.1%
Free cash flow margin0.1%5.5%-52.0%-106.5%-255.2%-377.3%-715.2%-790.6%-1,182.2%
Return on equity (ROE)-0.9%3.9%-6.7%-14.8%-29.6%-4.3%66.7%-14.6%-2.3%
Return on assets (ROA)-0.8%3.5%-6.5%-13.9%-28.3%-3.8%55.8%-11.8%—
Current ratio19.5918.8422.5414.1019.866.634.731.20—
Revenue growth24.6%34.8%0.6%34.4%38.2%96.7%95.9%285.2%—
EPS growth-118.2%————-106.3%———

Related